Voriconazole Tablets and Voriconazole Oral Suspension are generic equivalents of PF Prism C.V’s Vfend Tablets and Vfend Oral Suspension
Lupin has announced that its US subsidiary, Gavis Pharmaceuticals, (collectively Lupin) has received final approvals for its Voriconazole Tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/mL from the US FDA to market a generic equivalent of PF Prism C.V’s Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/mL. Lupin shall commence promoting the products in the US shortly.
Voriconazole tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/mL are the AB rated generic equivalent of PF Prism C.V’s Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/mL. It is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:
-
Invasive Aspergillosis
-
Candidemia in non-neutropenic patients and the following Candida infections: Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds
-
Esophageal Candidiasis
-
Serious fungal infections caused by Scedosporium apiospermum (Asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani in patients intolerant of or refractory to other therapy
Vfend Tablets, 50 mg and 200 mg had US sales of $92.8 million (IMS MAT March 2016) while Vfend Oral Suspension, 40 mg/mL had US sales of $15.9 million (IMS MAT March 2016).
Comments are closed.